Rigel Pharmaceuticals, Inc.
RIGL
$32.13
$2.769.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 10.28% | 20.73% | 25.59% | 176.01% | 80.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.28% | 21.19% | 25.59% | 176.01% | 80.58% |
| Cost of Revenue | 26.76% | 45.70% | -14.79% | 35.68% | 59.55% |
| Gross Profit | 5.06% | 15.13% | 39.56% | 217.12% | 88.47% |
| SG&A Expenses | 10.59% | 1.60% | 7.00% | 4.31% | -2.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.71% | 13.90% | -0.51% | 11.51% | 11.12% |
| Operating Income | -6.95% | 39.12% | 102.19% | 13,569.57% | 283.36% |
| Income Before Tax | 1.27% | 49.22% | 122.37% | 5,923.50% | 239.58% |
| Income Tax Expenses | 4,520.00% | -27,949.15% | -- | -- | -- |
| Earnings from Continuing Operations | -24.39% | 1,769.22% | 124.62% | 5,887.67% | 238.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.39% | 1,769.22% | 124.62% | 5,887.67% | 238.79% |
| EBIT | -6.95% | 39.12% | 102.19% | 13,569.57% | 283.36% |
| EBITDA | -6.69% | 37.73% | 97.88% | 5,721.70% | 303.73% |
| EPS Basic | -26.87% | 1,711.54% | 119.17% | 5,778.19% | 236.54% |
| Normalized Basic EPS | -2.05% | 44.63% | 116.96% | 5,811.44% | 237.32% |
| EPS Diluted | -30.16% | 1,598.73% | 108.57% | 5,566.67% | 233.84% |
| Normalized Diluted EPS | -6.54% | 35.58% | 104.86% | 5,724.25% | 234.60% |
| Average Basic Shares Outstanding | 3.39% | 3.18% | 2.49% | 1.91% | 1.64% |
| Average Diluted Shares Outstanding | 8.35% | 10.05% | 8.54% | 3.49% | 3.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |